

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3321531

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ALLOZYNE, INC.	05/06/2014
RECEIVING PARTY DATA		
Name:	MEDIMMUNE LIMITED	
Street Address:	MILSTEIN BUILDING, GRANTA PARK	
City:	CAMBRIDGE	
State/Country:	UNITED KINGDOM	
Postal Code:	CB21 6GH	
PROPERTY NUMBERS Total: 3		
Property Type	Number	
Application Number:	61705116	
Application Number:	61862495	
PCT Number:	EP2013069887	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(814) 474-2303	
Email:	mpytel@glancelaw.com	
Correspondent Name:	GLANCE LAW GROUP PC	
Address Line 1:	7200 VAN CAMP ROAD	
Address Line 4:	GIRARD, PENNSYLVANIA 16417	
ATTORNEY DOCKET NUMBER:	304.0039USWO	
NAME OF SUBMITTER:	NICHOLAS LINDGREN	
SIGNATURE:	/Nicholas Lindgren/	
DATE SIGNED:	04/22/2015	
Total Attachments: 9		
source=304-0039USWO_Allozyne-MedImmune#page1.tif		
source=304-0039USWO_Allozyne-MedImmune#page2.tif		
source=304-0039USWO_Allozyne-MedImmune#page3.tif		
source=304-0039USWO_Allozyne-MedImmune#page4.tif		

source=304-0039USWO_Allozyne-MedImmune#page5.tif
source=304-0039USWO_Allozyne-MedImmune#page6.tif
source=304-0039USWO_Allozyne-MedImmune#page7.tif
source=304-0039USWO_Allozyne-MedImmune#page8.tif
source=304-0039USWO_Allozyne-MedImmune#page9.tif

PATENT ASSIGNMENT

Pursuant to that certain Asset Purchase Agreement (the "PURCHASE AGREEMENT") of even date herewith by and between Allozyne, Inc. a Delaware corporation, having a place of business at 1600 Fairview Avenue East, Suite 300, Seattle, WA 98102 ("ASSIGNOR") and MedImmune Limited, having a place of business at Milstein Building, Grant Park, Cambridge CB21 6GH, United Kingdom ("ASSIGNEE"), for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR has sold, assigned, and transferred and does hereby sell, assign, and transfer to ASSIGNEE, for itself and its successors, transferees, and assignees, the following:


1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the patents and patent applications set forth on Exhibit A hereto ("PATENT RIGHTS"); and

2. The entire worldwide right, title, and interest in and to: (a) the PATENT RIGHTS, including any right of priority; (b) any divisional, continuation, substitute, renewal, reissue, and other related applications thereto which have been or may be filed in the United States or elsewhere in the world; (c) any patents which may be granted on the applications set forth in (a) and (b) above; and (d) the right to sue in its own name and to recover for past infringement of any or all of any applications or patents issuing therefrom.

ASSIGNOR agrees to do the following, as reasonably requested in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER of the above-identified Patent; and (3) generally do all lawful acts that ASSIGNEE reasonably requires for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER of the above mentioned Patent.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has made or will make hereafter no assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.


Duly Authorized Representative of ASSIGNOR


Meenu Chhabra, President and CEO

Date of Signature

May 6, 2014

Duly Authorized Representative of ASSIGNOR


Steven Gillis, Director and Chairman

[Handwritten signature]
3/30/15

25/12/11

✓ 3/20/5

✓ 3/24/11

[Handwritten signature]
5/20/10



3/5/14

Unpublished Assigned Intellectual Property

Allozyme (AZ) ref	Territory	Application Number	Filing Date	Title	Inventors	Owner	Status
P420USp	US	63/705,116	24 Sept 2012	Cell Lines	Marelli, VanBrunt, Grabstein	Allozyme	Converted into PCT

[Handwritten signature]
3/20/12

Allosyne (AZ) ref	Territory	Application Number	Filing Date	Title	Inventors	Owner	Status
P425USp	US	61/793,435	15 March 2013	Cell lines	Morelli, VanBrunt, Grabstein	Allosyne	Abandoned
P428USp	US	61/862,485	5 August 2013	Cell lines	Morelli, VanBrunt, Grabstein	Allosyne	Converted into PCT
P429PCT		PCT/EP2013/069887	24 September 2013	Cell lines	Morelli, VanBrunt, Grabstein	Allosyne	Pending Published March 2014
P430PCT		PCT/EP2013/069888	24 September 2013	Aminoacid derivatives	Morelli, VanBrunt, Grabstein	Allosyne	Pending Published March 2014


 3/20/14